<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><p>Non small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite improvements in treatment protocols the survival rate in NSCLC remains poor. An improved understanding of cancer biology has led to the investigation of angiogenesis in NSCLC development and progression by intratumoral microvessel count or expression of angiogenic markers. The prognostic significance of several frequently assessed angiogenic factors and current antiangiogenic strategies which proved to be particularly promising in combination with chemotherapeutic agents for clinical management of NSCLC are here reviewed.</p></abstract>

Non small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite improvements in treatment protocols the survival rate in NSCLC remains poor. An improved understanding of cancer biology has led to the investigation of angiogenesis in NSCLC development and progression by intratumoral microvessel count or expression of angiogenic markers. The prognostic significance of several frequently assessed angiogenic factors and current antiangiogenic strategies which proved to be particularly promising in combination with chemotherapeutic agents for clinical management of NSCLC are here reviewed.

Angiogenesis and Non Small Cell Lung Cancer

Department of Medical Genetics, Medical Faculty, Medical University Sofia, Sofia, Bulgaria

Balkan Journal of Medical Genetics

{"article-title":"Angiogenesis and Non Small Cell Lung Cancer"}

Non small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite improvements in treatment protocols the survival rate in NSCLC...

Angiogenesis and Non Small Cell Lung Cancer

Publié en ligne: 06 mai 2009

Pages: 3 - 10

DOI: https://doi.org/10.2478/v10034-008-0011-3

Mots clés
Angiogenesis, Non small cell lung cancer (NSCLC), Vascular endothelial growth factor (VEGF), Antiangiogenic agents

This content is open access.

Angiogenesis and Non Small Cell Lung Cancer

Publié en ligne: 06 mai 2009

Pages: 3 - 10

DOI: https://doi.org/10.2478/v10034-008-0011-3

Mots clésAngiogenesis, Non small cell lung cancer (NSCLC), Vascular endothelial growth factor (VEGF), Antiangiogenic agents

This content is open access.

Mots clés
Angiogenesis, Non small cell lung cancer (NSCLC), Vascular endothelial growth factor (VEGF), Antiangiogenic agents